Skip to main content
. Author manuscript; available in PMC: 2013 Apr 18.
Published in final edited form as: Oncogene. 2011 Dec 5;31(42):4559–4566. doi: 10.1038/onc.2011.539

Table 2.

The KRAS-variant is Associated with Platinum resistance

KRAS-variant Genotype Univariate Multivariate3
OR1 95% CI2 p OR 95% CI p
All
Non-variant (n=225) 1.00 1.00
Variant (n=66) 2.45 1.08 – 5.53 0.0313 3.18 1.31 – 7.72 0.0106
1

OR: odds ratio obtained from logistic regression

2

CI: confidence interval

3

Multivariate: adjusted for age, stage, grade, histology, residual disease after cytoreductive surgery, and treatment center

Studies: Yale, Italy #1, Italy #2